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Background: Current theories of tinnitus assume that the phantom sound is generated either through increased
spontaneous activity of neurons in the auditory brain, or through pathological temporal firing patterns of the
spontaneous neuronal discharge, or a combination of both factors. With this in mind, Tass and colleagues recently
tested a number of temporally patterned acoustic stimulation strategies in a proof of concept study. Potential
therapeutic sound regimes were derived according to a paradigm assumed to disrupt hypersynchronous neuronal
activity, and promote plasticity mechanisms that stabilize a state of asynchronous spontaneous activity. This would
correspond to a permanent reduction of tinnitus. The proof of concept study, conducted in Germany, confirmed
the safety of the acoustic stimuli for use in tinnitus, and exploratory results indicated modulation of tinnitus-related
pathological synchronous activity with potential therapeutic benefit. The most effective stimulation paradigm is
now in clinical use as a sound therapy device, the acoustic coordinated reset (CR®) neuromodulation (Adaptive
Neuromodulation GmbH (ANM), Köln, Germany).
Methods/Design: To measure the efficacy of CR® neuromodulation, we devised a powered, two-center,
randomized controlled trial (RCT) compliant with the reporting standards defined in the Consolidated Standards of
Reporting Trials (CONSORT) Statement. The RCT design also addresses the recent call for international standards
within the tinnitus community for high-quality clinical trials. The design uses a between-subjects comparison with
minimized allocation of participants to treatment and placebo groups. A minimization approach was selected to
ensure that the two groups are balanced with respect to age, gender, hearing, and baseline tinnitus severity. The
protocol ensures double blinding, with crossover of the placebo group to receive the proprietary intervention after
12 weeks. The primary endpoints are the pre- and post-treatment measures that provide the primary measures of
efficacy, namely a validated and sensitive questionnaire measure of the functional impact of tinnitus. The trial is also
designed to capture secondary changes in tinnitus handicap, quality (pitch, loudness, bandwidth), and changes in
tinnitus-related pathological synchronous brain activity using electroencephalography (EEG).
Discussion: This RCT was designed to provide a confident high-level estimate of the efficacy of sound therapy
using CR® neuromodulation compared to a well-matched placebo intervention, and uniquely in terms of sound
therapy, examine the physiological effects of the intervention against its putative mechanism of action.
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The phantom auditory sensation of tinnitus is transiently
experienced by most people, but for 10 to 15% of the
population, and up to one in three of older adults, the
experience is chronic [1,2]. Although factors contribut-
ing to tinnitus potentially include otologic, neurologic,
infectious, and drug-related effects, it is most readily as-
sociated with noise exposure and aging [3-5]. Among
the most frequently reported difficulties associated with
tinnitus are sleep disturbance, hearing difficulties, social
withdrawal, and negative emotional reactions, such as
anxiety and depression [6-10]. Intrusive tinnitus is,
therefore, a complex condition that arises with different
etiologies and comorbidities. Management of tinnitus
typically involves relieving the distress, anxiety or de-
pression that can accompany tinnitus, masking the
sound by introducing external sound, or reducing the
neural signal believed to be causing the tinnitus.
Current theories of tinnitus assume that the phantom
sound is generated either through increased spontaneous
activity of neurons in the auditory brain, or through patho-
logical synchrony of the spontaneous neuronal discharge,
or a combination of both factors (see Roberts et al. for a
review [11]). Theoretical modeling studies indicate that
such aberrant activity patterns might be reduced through
acoustic stimulation [12,13]. While Schaette and Kempter
[12] proposed that sound enrichment provided by pro-
longed use of a hearing aid could counteract neuronal
hyperactivity and reduce tinnitus, Tass and Popovych [13]
proposed using sound to interrupt pathological connectiv-
ity and synchronous firing that may underlie tinnitus in a
process termed ‘coordinated reset’ (CR®). CR® was first
modeled computationally by Tass [14] as a method using
high-frequency pulse trains to desynchronize the con-
certed activity of neural subpopulations. Tass et al. [15]
later generated evidence for applications in the domain of
deep brain electrical stimulation for neurological diseases,
such as Parkinson’s disease, using an animal model. Given
that the model of CR® was not specific to electrical stimuli,
Tass and Popovych [13] also modeled the potential CR®
effects of acoustic stimulation on tinnitus-related brain ac-
tivity, concluding it to hold promise as a tinnitus treat-
ment. Tass et al. [16] recently conducted a proof of
concept study on humans testing acoustic CR® algorithms
predicted to disrupt hypersynchronous neuronal activity,
and to promote plasticity that stabilizes a state of asyn-
chronous spontaneous activity. Such an effect would cor-
respond to a permanent reduction of tinnitus [13]. The
most effective stimulus paradigm is now in clinical use
as a sound therapy device, the acoustic CR® neuromodula-
tion (Adaptive Neuromodulation GmbH (ANM), Köln,
Germany). While the proof of concept study conducted by
Tass et al. [16] confirmed the safety of the sound stimulus,
it also provided exploratory level evidence that CR® neuro-modulation may be efficacious, in terms of reducing the
reaction to tinnitus and modulating tinnitus-related patho-
logical synchronous activity. However, a Phase 2 clinical
trial is now required to determine efficacy in a controlled
and powered sample.
Purpose
This Phase 2 randomized controlled trial (RCT) will deter-
mine whether the algorithmic auditory stimulation delivered
by the CR® neuromodulation device has significant benefit
over a placebo stimulus delivered by the same device.
Primary objectives
 Does CR® neuromodulation significantly reduce tinnitus
intrusiveness compared to an active placebo control?
Secondary objectives
 Does CR® neuromodulation significantly change the
percept of tinnitus compared to an active placebo
control?
 Does CR® neuromodulation significantly alter neural
temporal firing patterns, as measured by
spontaneous low-frequency oscillatory responses in
the brain (electroencephalography (EEG)), compared
to the placebo control?
Methods/Design
This is a two-center, double-blind, placebo-controlled
study with minimized allocation of participants to one of
two groups. Center 1 is the National Institute for Health
Research (NIHR) Nottingham Hearing Biomedical Re-
search Unit, Nottingham, UK. Center 2 is the University
College London (UCL) Ear Institute, London, UK. Par-
ticipants meeting the inclusion criteria will be random-
ized to either the intervention group (Group 1) or the
placebo group (Group 2) of a 12-week RCT. After 12
weeks, the placebo group will be unblinded and continue
on the study according to the treatment protocol. After
the RCT, all participants will be followed for a further 24
weeks in a long-term extension (LTE) arm (Figure 1).
The primary endpoints are the pre- and post-intervention
metrics that provide the primary measures of efficacy,
that is, responses about thoughts and feelings associated
with tinnitus measured using a validated questionnaire.
Repeated measures of general quality of life, tinnitus
handicap (as measured by two other tinnitus question-
naires), resting state EEG, and psychoacoustic measure
of tinnitus percept will also be collected as secondary
outcome measures.
Permission to conduct the study was granted by the
National Research Ethics Service (NRES) Committee,
East Midlands – Nottingham 1, Nottingham, UK, and
Figure 1 Trial flow chart. *Tinnitus assessment will include psychoacoustic (Tinnitus Tester) measures and questionnaire measures in the RCT
phase. Tinnitus Tester measures will not be taken in the LTE phase. EEG, electroencephalography; LTE, long-term extension; RCT, randomized
controlled trial.
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National Health Service (NHS) Trust, Research and
Innovation department, Nottingham, UK.
Population and sample size
Participants will be recruited through leaflets placed in
audiology, and ear, nose and throat (ENT) departments,
and any direct contacts made to the recruiting centers in
response to publicity in the national media. Written in-
formed consent will be obtained from each participant
in accordance with the permissions granted. The pri-
mary outcome measure of treatment efficacy is the Tin-
nitus Handicap Questionnaire (THQ) [17], where the
maximum score is 2,700. THQ data from a published
study of tinnitus maskers were used to estimate the re-
quired sample size (two-sample t-test power analysis,
performed in R). After a 12-week intervention, Henry et al.
[18] found that a difference in mean THQ score of 194
between groups with a pooled standard deviation (SD) of
450 was considered significant, and represented a medium
effect size. If we therefore assume a difference in mean
THQ score of 250 between groups with a pooled SD of
425 as representative of a large effect size, then for a two-
sided significance level of 0.05 and 80% power, it is esti-
mated that 47 participants are required for each group.
We assume a low drop-out rate of approximately 5%
in 12 weeks and therefore a total of 100 participants
will be recruited.Inclusion criteria
 Men and women ≥18 years of age
 Pure-tone average (PTA) hearing thresholds <60 dB HL
(0.5, 1, 2, 4 kHz) in the ear where tinnitus is perceived
 Must be able to hear stimulation tones presented by
the device at all frequencies
 Chronic subjective tinnitus for more than 3 months
 Dominant tinnitus frequency measured between 0.2
and 10 kHz
 At least mild tinnitus, score ≥18 on Tinnitus
Handicap Inventory (THI) [19]
 Willing to wear the device for 4 to 6 hours daily
during the trial
 Sufficient command of English language to read,
understand and complete the questionnaires
 Able and willing to give informed consent
Exclusion criteria
 Objective tinnitus, Ménière’s disease,
temporomandibular joint disorder
 Pulsatile tinnitus
 Intermittent tinnitus
 Severe anxiety, >25 score on the Beck Anxiety
Inventory (BAI) [20]
 Severe depression, >29 score on the Beck
Depression Inventory (BDI-II) [20]
Figure 2 Image of the acoustic CR® neuromodulation device.
CR, coordinated reset.
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 Hearing aid wearers for less than 9 months, or long-
term hearing aid wearers who have had prescription
adjustments within last 3 months
 Pure-tone absolute hearing thresholds >70 dB on
individual frequencies up to 8 kHz (unable to
sufficiently hear the stimulus)
 Taking part in another trial during the 30 days
before study start
 The individually tailored training stimulus is
uncomfortable or not acceptable to the
participant
Pure-tone audiometry will be conducted in a sound-
proof booth using the Unity 2 system (Siemens, Berlin,
Germany) and HDA 200 headphones (Sennheiser,
Wedemark, Germany), measuring hearing thresholds be-
tween 125 and 12,000 Hz.
Participants will be withdrawn from the trial at any
point if they commence any other form of tinnitus ther-
apy, or if following commencement of the study they re-
port an adverse event. The definition of an adverse event
in the context of this study is either: 1) since wearing
the device tinnitus intrusiveness increases and makes it
unbearable; or 2) a disease or symptom (unrelated to
tinnitus) present at baseline worsens following the start
of the study.
Randomization and blinding
Randomized allocation to groups will be based on a
minimization protocol (Minim) [21] and conducted by a
researcher who is independent of the trial. Minimization
will be used here to match groups for age: 18 to 49
years, 50 to 69 years, 70 or over years (categories based
on statistics for moderate to severe hearing loss sourced
from the Royal National Institute for Deaf People, now
Action on Hearing Loss [22]), gender, hearing loss (PTA
at 0.5, 1, 2, 4 kHz), and grade of tinnitus severity (using
THI categories defined in [23]).
Participants will be randomly assigned initially to re-
ceive the treatment (Group 1) or placebo (Group 2)
stimulation. After 12 weeks, participants in the placebo
group will crossover to start receiving the treatment
according to the intervention algorithm, and will follow
the same protocol as initially delivered to Group 1.
The RCT phase of this study will be conducted
double-blind. Participants will not know the group to
which they are allocated (intervention or placebo). The
researcher assessing outcomes will not know which
group the participant was allocated to. The audiologists
fitting and adjusting the device will be blind to group al-
location since they will be unaware whether the device
programming code supplied to them after the partici-
pant is randomized generates an intervention or placebostimulus. All participants will receive the same informa-
tion about the expected trial outcomes.
Intervention
The CR® neuromodulation device is small, lightweight,
and connected to a pair of custom in-ear earphones
(Figure 2). The device will be fitted by an appropriately
trained audiologist using a custom sound console to de-
termine a pitch matching the participant’s tinnitus per-
cept, and to calculate a unique sequence of tones around
that pitch to be employed in the treatment protocol for
each individual. The tones are presented by the device at
a level that is only slightly higher than the hearing
threshold for those tones, that is, a comfortable quiet
level that should not interrupt the participant’s normal
daily routine. Participants will be instructed to wear the
device for 4 to 6 hours daily during the RCT stage. Dur-
ing the LTE stage, participants in the intervention group
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daily.
Placebo control
Participants in the placebo group will also receive the
same device and be presented with a sequence of tones.
The placebo tones will include frequencies in the 500 to
4,000 Hz range, but excluding frequencies around the
tinnitus pitch. The placebo tones will also be delivered
at a slower repetition rate and are predicted not to have
the same therapeutic effect as the treatment stimulus.
The placebo does, however, represent an active interven-
tion, since the participant may experience some level of
tinnitus masking while the device is worn.
Device fitting procedure
The tinnitus assessment and the device programming pro-
cedure will be identical for all participants. The individual’s
dominant tinnitus pitch is determined using an adaptive
bracketing method. To first establish a ‘bracket’, pure tones
from 500 to 12,000 Hz are presented to the individual in an
ascending/descending sweep with a step size of 500 Hz,
and participants select tones that border similarity to their
tinnitus percept. Once this bracket has been established, a
two-alternate forced-choice method is used to determine a
dominant tinnitus pitch. Once a dominant pitch is reliably
identified, the proprietary software uses an algorithm to
program a set of four stimulation tones that span above
and below the tinnitus pitch. Tones are then loudness
matched, such that the participant subjectively equates each
tone to be at a soft but audible listening level. All tones are
compared against each other to ensure equal loudness.Figure 3 Device fitting protocol for differences in tinnitus percept be
one ear need be assessed.All participants are prescribed with bilateral stimula-
tion. Participants with unilateral tinnitus (experienced in
one ear) will be prescribed bilateral stimulation with the
same prescription. Participants with bilateral tinnitus
that differs in pitch between ears by more than 200 Hz
will require different stimulation prescriptions for each
ear. All participants who do not perceive tinnitus to be
in the ear will be prescribed bilateral stimulation with
the same prescription (Figure 3).
Participants will be reassessed at planned intervals
over the 36 weeks of the trial (Figure 1), or at an interim
interval if they experience a noticeable change in tin-
nitus pitch. The device prescription will be reassessed at
each visit, and when there is a change in tinnitus pitch it
will be adjusted accordingly. When a participant’s tin-
nitus pitch is increased beyond the output limits of the
device, that is, tinnitus at or above 10.5 kHz, the partici-
pant will pause using the device for 2 weeks, and will
then be reassessed. If at this assessment tinnitus remains
at or above 10.5 kHz, the participant will be withdrawn
from the trial.Primary outcome measure
The primary measure of efficacy will be change in THQ
score between baseline and week 12. At the time of writ-
ing the protocol for the funding application, this ques-
tionnaire was one of the better validated measures of
tinnitus severity, responsive to treatment-related change,
and with a test-retest reliability of 0.93 [24]. The sample
size is powered according to previous trial data using
this measure [18].tween ears. If tinnitus is identified as central (not in the ear) then only
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Questionnaires
The World Health Organization (WHO) Quality Of
Life-BREF (WHOQOL-BREF) is a 26-item questionnaire
measuring self-perceived quality of life in four domains
(physical health, psychological, social relationships, en-
vironment) with test-retest reliability of 0.66 to 0.80 [25].
In the UK, the THI is the most common clinical tool
used for diagnosis, and sometimes outcome assessment
[26]. It is a 25-item measure of tinnitus severity with
test-retest reliability of 0.93.
We will also add the Tinnitus Functional Index (TFI)
questionnaire [27] to the assessment battery. This 25-item
questionnaire was very recently developed as a sensitive
measure of treatment-related change in tinnitus distress
with a clinically significant change defined at 13 points. It
is also a diagnostic tool for tinnitus severity with high test-
retest reliability of 0.97.
Participants will also be provided with a paper diary
and asked to log their daily use of the device, and note
any experience or comment on its usability.
Psychoacoustic measures of tinnitus loudness and pitch
In addition to the pitch match performed as part of the
device fitting procedure, baseline and changes in tinnitus
quality (loudness, bandwidth, dominant pitch) will also
be assessed using the Tinnitus Tester developed by
Roberts et al. [11]. For loudness matching, participants
adjust the level of 11 sound clips (center frequencies 500
to 12,000 Hz) until each one is perceived to equal that
of the tinnitus sound. A sensation level is then calcu-
lated according to the matched value at a single fre-
quency where there is little or no hearing loss and the
frequency is distant from the dominant tinnitus pitch.
Next, a tinnitus spectrum representing bandwidth is
generated by asking participants to rate the likeness of
the same 11 sounds to the pitch of their tinnitus, using a
100-point scale. Bandwidth can then be calculated as the
SD of all frequencies in the tinnitus spectrum, where
each frequency is weighted by its percentage likeness to
the tinnitus pitch identified by the participant (compare
[28]). A dominant tinnitus pitch is taken as the fre-
quency in the spectrum with the highest likeness rating.
EEG spontaneous oscillatory activity
To assess changes in spontaneous oscillatory activity, EEG
will be performed using a Neuroscan system (SynAmps2
model 8050, Compumedics Neuroscan, Charlotte, NC,
USA) with 66 equidistant scalp electrodes. EEG will be
conducted at baseline and at the end of the 12-week RCT
for the first 50 participants (25 intervention, 25 placebo)
attending Center 1 in Nottingham. At the 12-week visit,
EEG will be performed after behavioral assessment, at a
minimum 2-hour break from stimulation. For the recor-ding, participants will be seated in a quiet, darkened
soundproof booth, have their eyes open and be instructed
to fix their gaze on a marker point in front of them. A
central frontal electrode will be used as ground and a
nose-tip electrode as reference, and two additional elec-
trodes will be placed below the eyes to monitor eye move-
ments. Electrode impedances will be maintained below
5 kΩ prior to the start of the recordings. EEG recordings
will be collected over a continuous 10-minute period with
a 0.5 to 200 Hz passband, and digitized at a 1,000 Hz sam-
pling rate.Statistical methods, data analysis and reporting
Analysis will be performed to include all 100 participants
who meet the study criteria and are fitted with the de-
vice. Participants leaving the study before its completion
will not be replaced. Any missing data will be imputed
using an expectation-maximization method, which as-
sumes a normal distribution for the partially missing
data and bases inferences on the likelihood under that
distribution (maximum 25 iterations, performed in SPSS
v16.0, IBM, Armonk, USA). Effect sizes will be calcu-
lated with Cohen’s d computed with the pooled SD of
the two groups.
Following completion of the trial, the sponsor will use
all reasonable endeavors to ensure the appropriate publi-
cation of the research. The manufacturer’s approval of the
manuscript will be sought prior to submission. However,
the investigators have the right to publish results of the
statistical analysis, conducted according to the protocol,
whether they are positive or negative, and whether
they support or negate the commercial interests of the
manufacturer.
Baseline characteristics of participants will be reported
as descriptive statistics, including but not limited to age,
gender, hearing levels, anxiety, depression, medication,
tinnitus duration, tinnitus severity, tinnitus dominant
pitch, and tinnitus loudness estimates. Comparisons be-
tween groups will assess the degree to which compar-
ability of randomization was achieved.Efficacy analyses
Our primary endpoint and first analysis of data will be
the end of the 12-week RCT. Analysis will involve a
summary of within- and between-group comparisons
with respect to the primary and secondary outcome
measures detailed above using paired t-test/McNemar’s
test, t-test, and analysis of variance (ANOVA)/Kruskal-
Wallis test analyses, as appropriate. In addition, (the
simple and/or multiple) linear regression/general linear
model/generalized linear model approaches will be
performed, adjusting for the factors employed in minim-
izing participants to groups, as appropriate.
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the 24-week stage to examine the effect of 12 weeks’
intervention across all 100 participants. The final ana-
lysis of long-term effects will examine all 100 partici-
pants at trial completion (36 weeks).
Subgroup analyses will be performed to identify a par-
ticipant population that demonstrates the most clinically
significant improvement.
EEG recordings (only performed on half of the partici-
pants) will be analyzed using EEGLAB [29], an open
source toolbox for advanced EEG analysis (Swartz Center
for Computational Neuroscience (SCCN), University of
California San Diego, CA, USA) run under MATLAB
(The Mathworks, Natick, MA, USA). Pre-processed data
(high- and low-pass filtering, offline epoching, artifact cor-
rection) will be further corrected for artifacts using inde-
pendent component analysis (ICA) in EEGLAB [30].
Power analysis will be carried out in the EEGLAB, and
obtained power spectra will be divided to analyze oscilla-
tory activity in normalized EEG frequency bands. Analysis
of sources of spontaneous oscillatory activity will also be
conducted in EEGLAB (and/or standardized low reso-
lution brain electromagnetic tomography (sLORETA)).
Non-parametric statistical tests will be used to test for sig-
nificant differences in any change in oscillatory activity be-
tween the placebo and intervention group. Within-group
comparisons of activity recorded pre- and post-intervention
will also be performed.
Safety analysis
Adverse events that occur during the trial will be recorded
and reported according to the trial sponsor’s standard
operating procedure (SOP) for medical device trials
(Nottingham University Hospitals NHS Trust SOP 52).
Discussion
Various forms of sound and sound enrichment are in use
for the clinical management of tinnitus. Typically sound is
used to either mask tinnitus (introduce enough sound en-
ergy to cover up the percept of tinnitus and provide a
temporary relief), partially mask tinnitus (reduce the per-
cept so that the patient can adjust or ‘habituate’ to the
sound), or to promote relaxation or distract attention
away from the tinnitus sound [31]. Such approaches
clearly target the psychological component of tinnitus (the
negative emotional reaction), but are not clearly linked to
any putative physiological mechanism of tinnitus gener-
ation. Acoustic CR® neuromodulation, however, explicitly
targets a physiological marker of tinnitus, that of patho-
logical synchronous oscillatory activity in the brain [32-35],
measurable using EEG.
To generate high-level evidence for the efficacy of CR®
neuromodulation, the RCT described here was designed
to meet the reporting standards defined in the Conso-lidated Standards of Reporting Trials (CONSORT) State-
ment [36]. The RCT design also addresses the recent call
for an international standard within the tinnitus commu-
nity [37] in the form of a powered, blinded RCT with a
mix of meaningful and validated outcome measures, to
best capture clinical significance and change in tinnitus
percept and related physiology.
Trial status
The trial is currently in recruitment phase.
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